Premium
Calcitonin gene‐related peptide in patients with endocrine tumors
Author(s) -
Takami Hiroshi,
Shikata JunIchi,
Kakudo Kennichi,
Ito Kunihiko
Publication year - 1990
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930430108
Subject(s) - calcitonin gene related peptide , calcitonin , medicine , medullary thyroid cancer , endocrine system , multiple endocrine neoplasia , endocrinology , thyroid , pheochromocytoma , pathology , immunohistochemistry , neuroendocrine tumors , medullary cavity , thyroid carcinoma , hormone , neuropeptide , receptor , gene , biology , biochemistry
The plasma level of calcitonin gene‐related peptide (CGRP) was measured by RIA in 41 patients with endocrine tumors [22 medullary thyroid carcinomas (MTC), seven parathyroid adenomas, four benign insulinomas, five carcinoids, and three pheochromocytomas]. Of the 22 patients with MTC, all five preoperative patients had elevated CGRP levels. The correlation between CGRP and calcitonin levels was significant ( P < .001) in 22 patients with MTC. Six of 19 patients with endocrine tumors other than MTC showed elevated CGRP levels. Immunohistochemical study showed that tumor tissues from all 22 cases of MTC and seven from other endocrine tumors contained immunoreactive CGRP. CGRP reactivity was found in only small numbers of tumor cells. Thus, although CGRP appeared to be a useful additional marker for MTC, the role of CGRP in the pathophysiology of endocrine tumors was not elucidated.